# National Research Corporation (NRC) Stock Analysis: A Deep Dive into Its High Return on Equity and Dividend Yield

- Link: https://www.directorstalkinterviews.com/national-research-corporation-nrc-stock-analysis-a-deep-dive-into-its-high-return-on-equity-and-dividend-yield/4121231163
- Published: 2025-12-18T11:14:19+00:00
- Author: Madison Wilson

National Research Corporation (NRC), a key player in the Health Information Services
industry, has carved a niche by providing analytics and insights to improve patient
and employee experiences across healthcare organizations. Despite a modest market
capitalization of $429.9 million, NRC’s financial metrics offer intriguing insights
for potential investors navigating the healthcare sector.

The most striking aspect of NRC’s financial profile is its impressive Return on 
Equity (ROE) of 66.87%. This figure is significantly above industry averages, indicating
that the company is highly efficient in generating profits from its equity base.
Such a high ROE could signal that NRC is using its resources effectively to create
shareholder value, a critical consideration for investors seeking robust returns.

NRC’s current stock price is $18.64, nestled near the upper bound of its 52-week
range of $10.13 to $18.73. This suggests the stock has experienced a positive trajectory,
reflecting market confidence or potentially successful strategic initiatives over
the past year. However, the lack of recent buy, hold, or sell ratings from analysts,
coupled with the absence of a target price range, makes it challenging to predict
future price movements based solely on external assessments.

Financially, NRC’s revenue growth has seen a slight decline of 3.40%, which may 
raise concerns about its growth prospects. Nevertheless, the company maintains a
healthy free cash flow of $7.57 million, which supports its operations and dividends.
Speaking of dividends, NRC offers a yield of 2.79%, with a payout ratio of 67.61%.
For income-focused investors, this yield presents an attractive opportunity, especially
in a low-interest-rate environment.

On the technical front, NRC’s moving averages suggest a stable stock with the 50-
day moving average at $14.70 and the 200-day moving average at $14.35. Additionally,
the Relative Strength Index (RSI) stands at 44.63, indicating that the stock is 
neither overbought nor oversold at this juncture. The MACD and Signal Line, both
positive, suggest a bullish trend, albeit investors should exercise caution given
the broader market conditions and macroeconomic factors affecting the healthcare
sector.

NRC’s business model centers around subscription-based solutions, offering actionable
insights into patient experiences and healthcare brand management. This positions
the company to capitalize on the growing demand for data-driven healthcare solutions.
Furthermore, innovations such as the Huey AI engine enhance NRC’s competitive edge,
potentially driving future growth and expanding its market share.

Founded in 1981 and headquartered in Lincoln, Nebraska, NRC has a long-standing 
history in the healthcare analytics field. This longevity, combined with its innovative
offerings, underscores its potential as a resilient investment in a rapidly evolving
industry.

For investors, NRC presents a mixed bag: a high ROE and stable dividend yield are
appealing, but the lack of clear growth in revenue and analyst guidance requires
careful consideration. As always, potential investors should weigh these factors
against their own risk tolerance and investment goals, considering the broader market
dynamics and trends within the healthcare sector.

Share on:
